AEON BIOPHARMA
AEON Biopharma is a biopharmaceutical company focused on the development of ABP-450, a proprietary 900 kDabotulinum toxin complex, for debilitating medical conditions. The company is dedicated to developing novel and proprietary treatment paradigms in order to improve patient outcomes and drive increased value for patients, physicians, and payers.
AEON BIOPHARMA
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2013-01-01
Address:
Newport Beach, California, United States
Country:
United States
Website Url:
http://www.aeonbiopharma.com
Total Employee:
1+
Status:
Active
Contact:
+1-949-298-2211
Email Addresses:
[email protected]
Total Funding:
45 M USD
Technology used in webpage:
Domain Not Resolving Euro Google Tag Manager Google Analytics Global Site Tag HSTS ReCAPTCHA Cloudflare Hosting Google Universal Analytics ReCAPTCHA V2
Similar Organizations
AbbVie
AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Aprea
Aprea is a biopharmaceutical company that develops novel cancer therapeutics.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Hansa Biopharma
Hansa Biopharma is an innovative and rapidly growing biopharmaceutical company that leverages its unique enzyme technology.
Osteal Therapeutics
Osteal Therapeutics is a clinical stage specialty pharmaceutical company developing novel treatments for orthopedic infections.
Scilex Pharmaceuticals
Scilex Pharmaceuticals is an emerging pharmaceutical company focused on acquiring and commercializing late-stage prescription products.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Employees Featured
Founder
Stock Details
Investors List
Daewoong Pharmaceutical
Daewoong Pharmaceutical investment in Post-IPO Debt - AEON Biopharma
Official Site Inspections
http://www.aeonbiopharma.com Semrush global rank: 5.27 M Semrush visits lastest month: 1.46 K
- Host name: 104.21.6.61
- IP address: 104.21.6.61
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "AEON Biopharma"
Investors - Governance - Governance Documents - AEON Biopharma
Nominating and Corporate Governance Committee Charter (opens in new window). 73 KB. Code of Business Conduct and Ethics (opens in new window)See details»
AEON Biopharma - Crunchbase Company Profile
Organization. AEON Biopharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact …See details»
Breaking new ground with therapeutic botulinum toxin …
Our team is on a mission to realize the untapped possibilities of therapeutic neurotoxins with our proprietary botulinum toxin complex. Our deep expertise in commercial neurotoxins guides us in establishing a new standard of …See details»
AEON Biopharma, Inc. (AEON) Company Profile & Facts - Yahoo …
See the company profile for AEON Biopharma, Inc. (AEON) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
AEON Biopharma - Investor Relations
Apr 21, 2025 AEON Biopharma is the only company dedicated exclusively to the use of botulinum toxins for therapeutic-only indications. With ABP-450 (prabotulinumtoxinA), we are …See details»
AEON Biopharma, Inc. | LinkedIn
AEON Biopharma is a biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions.See details»
Shawn Park - AEON Biopharma
Park has been a director at Daewoong since March 2023 and was a director at Daewoong Co., Ltd., an affiliate of Daewoong, from March 2021 to March 2023. In addition, Mr. Park is …See details»
AEON Biopharma, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for AEON Biopharma, Inc. of Irvine, CA. Get the latest business insights from Dun & Bradstreet.See details»
AEON Biopharma (AEON) Company Profile & Description - Stock …
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical …See details»
AEON Biopharma - The Org
AEON Biopharma is a biopharmaceutical company that develops novel and proprietary treatment paradigms to improve patient outcomes.See details»
AEON Biopharma - AEON Biopharma Reports Fourth Quarter and …
Mar 29, 2024 The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To …See details»
AEON Biopharma - Craft
Oct 29, 2024 Net income (Q3, 2024)($6.2M) Cash (Q3, 2024)$537.0K EBIT (Q3, 2024)($4.0M) Enterprise value $40.3MSee details»
AEON BioPharma - 2025 Company Profile - Tracxn
Apr 3, 2025 AEON BioPharma is a series C company based in Newport Beach (United States), founded in 2018.It operates as a Provider of bio-therapeutics to treat nervous system-related conditions.See details»
AEON Biopharma Announces NYSE American Acceptance of Plan
6 days ago To learn more about AEON, visit www.aeonbiopharma.com. Forward-Looking Statements . Certain statements in this press release may be considered forward-looking …See details»
AEON Biopharma 2025 Company Profile: Stock Performance
AEON Biopharma General Information Description. AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex …See details»
AEON Biopharma Appoints Rob Bancroft as President and CEO
Apr 21, 2025 AEON Biopharma announces Rob Bancroft as new CEO to advance ABP-450 program targeting therapeutic indications. Quiver AI Summary. AEON Biopharma, Inc., a …See details»
Press Release Details - investors.aeonbiopharma.com
IRVINE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) - AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company …See details»
AEON Biopharma to Become Publicly Listed via Merger with
Dec 13, 2022 [email protected]. Investor Contact: Corey Davis, Ph.D. LifeSci Advisors +1 212 915 2577 [email protected]. Priveterra Contacts: …See details»
Company AEON Biopharma, Inc. Nasdaq - MarketScreener.com
Jan 31, 2017 AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an …See details»
Chad Oh, MD - AEON Biopharma
Chad Oh, MD, our Chief Medical Officer, has more than 30 years of therapeutic clinical development experience in both industry and academia with a focus on CNS, infectious, …See details»